SRR25617855
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.430
- UV_RESPONSE_DN+0.200
- MYOGENESIS+0.130
- ESTROGEN_RESPONSE_EARLY+0.110
- APICAL_SURFACE+0.080
- ANGIOGENESIS+0.040
- SPERMATOGENESIS+0.040
- ANDROGEN_RESPONSE+0.030
- COAGULATION+0.020
- FATTY_ACID_METABOLISM+0.000
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.450
- MTORC1_SIGNALING-0.410
- E2F_TARGETS-0.400
- ALLOGRAFT_REJECTION-0.390
- G2M_CHECKPOINT-0.390
- INTERFERON_GAMMA_RESPONSE-0.390
- MYC_TARGETS_V2-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.320
- GLYCOLYSIS-0.310
- DNA_REPAIR-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_17_0022_E1_S60 | — | A | 0.889 |
| 2 | SRR10900003 | — | — | 0.873 |
| 3 | SRR1488672 | GTEX | — | 0.872 |
| 4 | SRR8518225 | — | B | 0.870 |
| 5 | SRR1471350 | GTEX | — | 0.870 |
| 6 | TCGA-OL-A66K-01A-11R-A29R-07 | — | B | 0.869 |
| 7 | SRR33532757 | — | A | 0.869 |
| 8 | SRR8613701 | — | A | 0.867 |
| 9 | C3N-03921 | — | cohortA1 | 0.865 |
| 10 | C3L-00444 | — | cohortA1 | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |
| COAGULATION | 0.020 | Binimetinib | — uncovered |